AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Mitochondrial adenyl nucleotide antiporter SLC25A23

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9BV35

UPID:

SCMC3_HUMAN

Alternative names:

Mitochondrial ATP-Mg/Pi carrier protein 2; Short calcium-binding mitochondrial carrier protein 3; Solute carrier family 25 member 23

Alternative UPACC:

Q9BV35; B4DGB6; Q4LBC2; Q705K3; Q86Y43; Q8N2N4; Q96NQ4

Background:

The Mitochondrial adenyl nucleotide antiporter SLC25A23, also known as Mitochondrial ATP-Mg/Pi carrier protein 2 and Short calcium-binding mitochondrial carrier protein 3, plays a crucial role in cellular energy management. It facilitates the transport of adenine nucleotides across the inner mitochondrial membrane, balancing the mitochondrial matrix adenine nucleotide pool in response to cellular energetic demands. This protein also regulates mitochondrial calcium uptake and may transport divalent metal cations in complex with ATP.

Therapeutic significance:

Understanding the role of Mitochondrial adenyl nucleotide antiporter SLC25A23 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.